BioLineRX
BLRX
16 hedge funds and large institutions have $5.42M invested in BioLineRX in 2020 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
47% more capital invested
Capital invested by funds: $3.69M → $5.42M (+$1.73M)
23% more funds holding
Funds holding: 13 → 16 (+3)
0.01% less ownership
Funds ownership: 0.04% → 0.03% (-0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$377K |
| 2 |
Renaissance Technologies
New York
|
+$269K |
| 3 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
+$200K |
| 4 |
Goldman Sachs
New York
|
+$64.6K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$32.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Senvest Management
New York
|
-$124K |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$79.7K |
| 3 |
Jane Street
New York
|
-$77K |
| 4 |
NFG
Next Financial Group
Houston,
Texas
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BI
1
BVF Inc
San Francisco,
California
| $2.88M | -$79.7K | -1,167 | -3% |
|
|
2
Morgan Stanley
New York
| $966K | +$377K | +5,530 | +64% |
|
|
SM
3
Senvest Management
New York
| $772K | -$124K | -1,815 | -14% |
|
|
4
Renaissance Technologies
New York
| $269K | +$269K | +3,934 | New |
|
|
PVH
5
Psagot Value Holdings
Tel Aviv,
Israel
| $200K | +$200K | +2,925 | New |
|
|
O
6
OrbiMed
New York
| $118K | – | – | – |
|
|
7
Goldman Sachs
New York
| $65K | +$64.6K | +947 | New |
|
8
LPL Financial
San Diego,
California
| $34K | +$15.4K | +225 | +83% |
|
|
9
Acadian Asset Management
Boston,
Massachusetts
| $32K | +$32.4K | +474 | New |
|
|
CCB
10
Cutter & Co Brokerage
Ballwin,
Missouri
| $30K | +$6.83K | +100 | +29% |
|
|
OM
11
Opaleye Management
Boston,
Massachusetts
| $29K | – | – | – |
|
12
Creative Planning
Overland Park,
Kansas
| $20K | +$19.8K | +290 | New |
|
|
ADL
13
Asset Dedication LLC
San Francisco,
California
| $1K | – | – | – |
|
|
RE
14
RBC Europe
London,
United Kingdom
| $22 | – | – | – |
|
|
15
Jane Street
New York
| – | -$77K | -1,301 | Closed |
|
|
NFG
16
Next Financial Group
Houston,
Texas
| – | -$5K | -90 | Closed |
|
BLRX Hedge Fund Activity: Q2 2020 in Review
16 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q2 2020, worth a combined $5.42M — up 47% from $3.69M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BLRX positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $377K. The largest seller was Senvest Management, cutting an estimated $124K.
- 16 institutional investors held BioLineRX (BLRX) as of Q2 2020, up from 13 in Q1 2020.
- Funds reported $5.42M of BioLineRX stock for Q2 2020, up 47% quarter-over-quarter.
- 5 funds opened new BioLineRX positions in Q2 2020 and 2 closed out, a net change of +3 holders.
- The largest BioLineRX buyer in Q2 2020 was Morgan Stanley, an estimated $377K added.
- The largest BioLineRX seller in Q2 2020 was Senvest Management, an estimated $124K sold.
Based on aggregated 13F filings for Q2 2020.